EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibiotic Therapy Duration for Multidrug-Resistant Gram-Negative Bacterial Infections: An Evidence-Based Review

Andrea Marino iD, Egle Augello iD, Carlo Maria Bellanca iD, Federica Cosentino, Stefano Stracquadanio iD, Luigi La Via iD, Antonino Maniaci iD, Serena Spampinato, Paola Fadda, Giuseppina Cantarella iD, Renato Bernardini, Bruno Cacopardo und 1 weitere

International Journal of Molecular Sciences · 18.07.2025 · 26 (14) · 6905

DOI: 10.3390/ijms26146905 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.07.2025. Verfasst von Andrea Marino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, ARNAS Garibaldi Hospital, 95122 Catania, Italy. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Gram-Negative Bacterial Infections, Gram-Negative Bacteria. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Determining the optimal duration of antibiotic therapy for infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) is a critical challenge in clinical medicine, balancing therapeutic efficacy against the risks of adverse effects and antimicrobial resistance. This narrative review synthesises current evidence and guidelines regarding antibiotic duration for MDR-GNB infections, emphasising bloodstream infections (BSI), hospital-acquired and ventilator-associated pneumonia (HAP/VAP), complicated urinary tract infections (cUTIs), and intra-abdominal infections (IAIs). Despite robust evidence supporting shorter courses (3–7 days) in uncomplicated infections caused by more susceptible pathogens, data guiding optimal therapy duration for MDR-GNB remain limited, particularly concerning carbapenem-resistant Enterobacterales (CRE), difficult-to-treat Pseudomonas aeruginosa (DTR-Pa), and carbapenem-resistant Acinetobacter baumannii (CRAB). Current guidelines from major societies, including IDSA and ESCMID, provide explicit antimicrobial selection advice but notably lack detailed recommendations on the duration of therapy. Existing studies demonstrate non-inferiority of shorter versus longer antibiotic courses in specific clinical contexts but frequently exclude critically ill patients or those infected with non-fermenting MDR pathogens. Individualised duration decisions must integrate clinical response, patient immunologic status, infection severity, source control adequacy, and pharmacologic considerations. Significant knowledge gaps persist, underscoring the urgent need for targeted research, particularly randomised controlled trials assessing optimal antibiotic duration for the most challenging MDR-GNB infections. Clinicians must navigate considerable uncertainty, relying on nuanced judgement and close monitoring to achieve successful outcomes while advancing antimicrobial stewardship goals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialGram-Negative Bacterial InfectionsGram-Negative BacteriaHumansDuration of TherapyEvidence-Based Medicine

Stichwörter der Autor:innen

Gram-negative bacterial infectionsantibiotic durationantibiotics PK/PDantimicrobial stewardshipmultidrug-resistant bacteriatreatment guidelines

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, ARNAS Garibaldi Hospital, 95122 Catania, Italy.
  • Department of Biomedical and Biotechnological Science, Section of Pharmacology, University of Catania, 95123 Catania, Italy.
  • Clinical Toxicology Unit, University Hospital of Catania, 95123 Catania, Italy.
  • Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, 95123 Cagliari, Italy.
  • Department of Medicine and Surgery, University of Enna "Kore", 94100 Enna, Italy.
  • Department of Anesthesia and Intensive Care, University Hospital Policlinico "G. Rodolico-San Marco", 24046 Catania, Italy.

ORCID-Profile: Andrea Marino, Egle Augello, Carlo Maria Bellanca, Stefano Stracquadanio, Luigi La Via, Antonino Maniaci, Giuseppina Cantarella, Giuseppe Nunnari

Zitieren

APA

Marino, A., Augello, E., Bellanca, C. M., Cosentino, F., Stracquadanio, S., La Via, L., Maniaci, A., Spampinato, S., Fadda, P., Cantarella, G., Bernardini, R., Cacopardo, B., & Nunnari, G. (2025). Antibiotic Therapy Duration for Multidrug-Resistant Gram-Negative Bacterial Infections: An Evidence-Based Review. International Journal of Molecular Sciences, 26(14), 6905. https://doi.org/10.3390/ijms26146905

Vancouver

Marino A, Augello E, Bellanca CM, Cosentino F, Stracquadanio S, La Via L, et al. Antibiotic Therapy Duration for Multidrug-Resistant Gram-Negative Bacterial Infections: An Evidence-Based Review. International Journal of Molecular Sciences. 2025;26(14):6905. doi:10.3390/ijms26146905

BibTeX
@article{Marino2025,
  author = {Marino, Andrea and Augello, Egle and Bellanca, Carlo Maria and Cosentino, Federica and Stracquadanio, Stefano and La Via, Luigi and Maniaci, Antonino and Spampinato, Serena and Fadda, Paola and Cantarella, Giuseppina and Bernardini, Renato and Cacopardo, Bruno and Nunnari, Giuseppe},
  title = {Antibiotic Therapy Duration for Multidrug-Resistant Gram-Negative Bacterial Infections: An Evidence-Based Review},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {14},
  pages = {6905},
  doi = {10.3390/ijms26146905}
}
Kostenlos starten →